Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce its best in class av?6 Integrin platform technology has been featured in prestigious research journal Cancers.
Radiopharm’s av?6 platform was invented by highly regarded Integrin expert Professor Johannes Notni, with evidence that the av?6 Integrin is found in a variety of challenging cancers including pancreatic, head and neck, and certain lung cancers. It may provide outstanding performance in radiolabelling (tracking the movement / breakdown of target molecules) with the Ga-68 radiopharmaceutical tracer, showing promise in the early detection of these cancers using PET imaging.
The manuscript published in Cancers, titled ‘It’s Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals’, investigated recent research on other radiolabelled integrin ligands and the potential clinical benefit that may result from their development.
For more information, download the attached PDF.
Download this document
